CA3214273A1 - Methods of administering long-acting growth hormone polypeptides - Google Patents

Methods of administering long-acting growth hormone polypeptides Download PDF

Info

Publication number
CA3214273A1
CA3214273A1 CA3214273A CA3214273A CA3214273A1 CA 3214273 A1 CA3214273 A1 CA 3214273A1 CA 3214273 A CA3214273 A CA 3214273A CA 3214273 A CA3214273 A CA 3214273A CA 3214273 A1 CA3214273 A1 CA 3214273A1
Authority
CA
Canada
Prior art keywords
subject
long
rhgh
dose level
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214273A
Other languages
English (en)
French (fr)
Inventor
Jose Francisco Cara
Aleksandra Pastrak
Srinivas Rao VALLURI
Michael Paul WAJNRAJCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Pfizer Inc
Original Assignee
Opko Biologics Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd, Pfizer Inc filed Critical Opko Biologics Ltd
Publication of CA3214273A1 publication Critical patent/CA3214273A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3214273A 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides Pending CA3214273A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163163504P 2021-03-19 2021-03-19
US63/163,504 2021-03-19
US202163272417P 2021-10-27 2021-10-27
US63/272,417 2021-10-27
PCT/US2022/020804 WO2022197961A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Publications (1)

Publication Number Publication Date
CA3214273A1 true CA3214273A1 (en) 2022-09-22

Family

ID=83320806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214273A Pending CA3214273A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Country Status (10)

Country Link
US (1) US20240166710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308151A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022145646A (cg-RX-API-DMAC7.html)
KR (1) KR20230171936A (cg-RX-API-DMAC7.html)
AU (1) AU2022238386A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018980A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214273A1 (cg-RX-API-DMAC7.html)
IL (1) IL305661A (cg-RX-API-DMAC7.html)
MX (1) MX2023010997A (cg-RX-API-DMAC7.html)
WO (1) WO2022197961A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
HUE050002T2 (hu) * 2013-10-21 2020-11-30 Opko Biologics Ltd Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
EP4732848A3 (en) * 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
KR102527180B1 (ko) * 2014-12-10 2023-04-27 옵코 바이오로직스 리미티드 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법
MY184625A (en) * 2014-12-10 2021-04-09 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides

Also Published As

Publication number Publication date
BR112023018980A2 (pt) 2023-12-05
EP4308151A4 (en) 2025-02-26
EP4308151A1 (en) 2024-01-24
WO2022197961A1 (en) 2022-09-22
KR20230171936A (ko) 2023-12-21
US20240166710A1 (en) 2024-05-23
JP2022145646A (ja) 2022-10-04
MX2023010997A (es) 2023-11-28
AU2022238386A1 (en) 2023-09-14
IL305661A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12029780B2 (en) Long-acting polypeptides and methods of producing and administering same
Høybye et al. Status of long-acting-growth hormone preparations—2015
Reh et al. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review
Smith et al. A growth differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons
US20140162954A1 (en) Fusion of human growth hormone and albumin formulation and uses thereof
TWI777407B (zh) 長效型多肽及其生產和給藥的方法
Kemp Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options
US20240166710A1 (en) Methods of administering long-acting growth hormone polypeptides
CN117425490A (zh) 施用长效生长激素多肽的方法
EP1501539A1 (en) Method for control of depression using c terminal growth hormone (gh) fragment
Yuen et al. Long-acting growth hormone preparations
HK40098775A (en) Methods of administering long-acting growth hormone polypeptides
Dao et al. Human growth hormone
Çetinkaya et al. Long-acting growth hormone therapy, rational and future aspects
Wang et al. Tesamorelin, a human growth hormone releasing factor analogue
US20070066519A1 (en) Use of human growth hormone in multiple system atrophy
US20250325560A1 (en) Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
Dao et al. Human growth hormone
Luz et al. History and Current Status of Growth Hormone Treatment in Children: CC Luz, PF Collett-Solberg
US20200000884A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
Steelman et al. Cara, CL Roland, CT Taylor, SR Valluri, and MP Wajnrajch are employees
Ying et al. Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial
Class et al. Patent application title: FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN FORMULATION AND USES THEREOF Inventors: Kurt Brown (Narbeth, PA, US) Merav Bassan (Netanya, IL) Assignees: Teva Pharmaceutical Industries Ltd.
Ribeiro Somatrogon. Long-acting human growth hormone, Treatment of human growth hormone deficiency
Kochar Recent Trends in Use of Growth Hormone Therapy

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260323

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260323

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260323

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324